Meta-Analysis Confirms Nirsevimab’s Real-World Effectiveness Against Severe RSV in Infants

A 27-study review shows the monoclonal antibody significantly reduces RSV-related hospitalizations, ICU admissions, and respiratory infections while highlighting variability across age groups and regions.